Preliminary biomarker evaluations have indicated that baseline soluble VEGFR and phosphorylated extracellular signal-regulated kinase levels are indicative of the sorafenib response in RCC (25) and HCC (26), respectively. This evidence concerns the gene KDR and hepatocellular carcinoma.